China Biopharmaceutical (01177) has announced that the Group has entered into a strategic option and license agreement with Boehringer Ingelheim. This marks the second collaboration between the two parties in the oncology field, as both sides aim to establish a long-term strategic partnership.
The agreement covers six preclinical asset programs involving antibody-drug conjugates (ADCs) and T-cell engagers (TCEs). Five of these programs originate from the Group's wholly-owned subsidiary Lixin Pharmaceutical Technology (Shanghai) Co., Ltd., while one program comes from the Group's affiliated company Beijing Tide Pharmaceutical Co., Ltd.
Under the terms of the agreement, the Group will lead the early-stage development of these programs through the completion of global Phase I clinical trials. Upon achieving agreed clinical milestones, Boehringer Ingelheim has the right to exercise its option to obtain exclusive rights for development, manufacturing, and commercialization of (i) four of the programs globally (excluding mainland China, Hong Kong, and Macau) and (ii) the remaining two programs on a global basis.
The Group will receive US$358 million in upfront and near-term payments, and is entitled to potential option exercise, development, regulatory, and commercialization milestone payments totaling US$7 billion, as well as tiered royalties at up to double-digit rates based on future product sales.
This strategic collaboration with Boehringer Ingelheim represents a significant milestone in the Group's international innovation strategy, further validating the Group's R&D capabilities in next-generation oncology therapies. By combining the Group's innovation platforms and early-stage R&D capabilities with Boehringer Ingelheim's global oncology expertise, both parties aim to fully unlock the potential of these programs and bring innovative treatment options to patients worldwide.
Comments